Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation.

BACKGROUND Direct correlation of assessments of a validated composite measure such as the Asthma Control Questionnaire (ACQ) and risk of exacerbation has not been previously demonstrated in a randomized controlled trial. OBJECTIVE To evaluate the ability of the ACQ score over time to predict risk of a future asthma exacerbation. METHODS This analysis included data from a 12-week placebo-controlled trial (N = 292) of AMG 317, an IL-4 receptor α antagonist, in patients with moderate to severe atopic asthma. At baseline, patients had an ACQ score ≥1.5. Exacerbations were defined as requirement for systemic corticosteroids. A Cox proportional hazards model was used, with ACQ score as the time-dependent covariate. The analysis was repeated for individual components of the ACQ. RESULTS Each 1-point increase in ACQ was associated with a 50% increased risk of exacerbation (hazard ratio, 1.50; 95% CI, 1.03-2.20) for the following 2-week period. Evaluation of individual ACQ components also demonstrated a similar trend, though each to a lesser degree than the full composite ACQ. CONCLUSION Although based on a retrospective analysis, with small number of exacerbations, these findings support the utility of the composite ACQ score measurement to predict risk of future exacerbation in clinical trials and clinical practice. The composite ACQ score measurement was found to be a better predictor of future risk than individual ACQ components.

[1]  L. Boulet,et al.  Suboptimal asthma control: prevalence, detection and consequences in general practice , 2008, European Respiratory Journal.

[2]  A David Paltiel,et al.  A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. , 2004, Chest.

[3]  W. Busse,et al.  Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study , 2006, BMC pulmonary medicine.

[4]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[5]  Barrett T. Kitch,et al.  FEV(1) is associated with risk of asthma attacks in a pediatric population. , 2001, The Journal of allergy and clinical immunology.

[6]  K. Rabe,et al.  Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. , 2000, The European respiratory journal.

[7]  D. Fabian,et al.  The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.

[8]  K. Kuntz,et al.  Forced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma , 2006, Pediatrics.

[9]  S. Peters,et al.  Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. , 2007, The Journal of allergy and clinical immunology.

[10]  Brigit VanGraafeiland,et al.  National Asthma Education and Prevention Program. , 2002, The Nurse practitioner.

[11]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[12]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[13]  S. Weiss,et al.  The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. , 2002, American journal of respiratory and critical care medicine.

[14]  E. Bleecker,et al.  Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. , 2009, The Journal of allergy and clinical immunology.

[15]  P. Allison.  Survival analysis using the SAS system : a practical guide , 1995 .

[16]  C. Lyttle,et al.  Trends in the cost of illness for asthma in the United States, 1985-1994. , 2000, The Journal of allergy and clinical immunology.

[17]  N. Zhong,et al.  Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. , 2003, The Journal of allergy and clinical immunology.

[18]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[19]  Toshiyuki Yamagata,et al.  The Strategy for Predicting Future Exacerbation of Asthma Using a Combination of the Asthma Control Test and Lung Function Test , 2009, The Journal of asthma : official journal of the Association for the Care of Asthma.

[20]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[21]  Christine Jenkins,et al.  Overall asthma control: the relationship between current control and future risk. , 2010, The Journal of allergy and clinical immunology.

[22]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[23]  A. Buist,et al.  Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. , 2007, Chest.

[24]  Linda Abetz,et al.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. , 2006, Respiratory medicine.

[25]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[26]  Sally E Wenzel,et al.  A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.